Compare Neurocrine Biosciences Inc (NBIX) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Charles Schwab Corporation Common Stock — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Charles Schwab Corporation Common Stock trades at $100.17 (market cap $178.33B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 10.2× Neurocrine Biosciences Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.25% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SCHW | |
|---|---|---|
Market Cap | $17.40B | $178.33B |
Sector | Health | Financials |
52-Week High | $180.55 | $107.21 |
52-Week Low | $123.10 | $85.35 |
Enterprise Value | $16.49B | — |
Dividend Yield | — | 1.25% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
